Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
GUD Stock Chart & Stats
C$6.04
-C$0.03(-0.46%)
At close: 4:00 PM EST
C$6.04
-C$0.03(-0.46%)
Day’s Range― - ―
52-Week RangeC$5.11 - C$6.55
Previous CloseN/A
Volume40.10K
Average Volume (3M)48.52K
Market Cap
$578.13M
Enterprise ValueC$594.39M
Total Cash (Recent Filing)$116.42M
Total Debt (Recent Filing)$104.74M
Price to Earnings (P/E)1705.9
Beta0.32
Next Earnings
Mar 19, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding99,677,925
10 Day Avg. Volume49,308
30 Day Avg. Volume48,518
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)0.68
Price to Sales (P/S)1.45
P/FCF Ratio112.22
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda11.42
Forecast
1Y Price Target
$8.49Price Target Upside40.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsKnight reported strong third-quarter results, exceeding expectations.
Financial GuidanceThe company increased its financial guidance, suggesting confidence in future performance.
Revenue GrowthKnight Therapeutics' acquisitions, particularly Paladin and Sumitomo, have contributed positively to revenue growth.
Bears Say
Knight Therapeutics News
GUD FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was C$5.11 and its highest was C$6.55 in the past 12 months.
What is Knight Therapeutics’s market cap?
Knight Therapeutics’s market cap is $578.13M.
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 105 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on Nov 06, 2025. The company reported -C$0.04 earnings per share for the quarter, missing the consensus estimate of -C$0.007 by -C$0.033.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is -0.01.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 99,677,925 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of -C$0.04 in its last earnings report, missing expectations of -C$0.007. Following the earnings report the stock price went up 3.938%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in TSE:GUD
Company Description
Knight Therapeutics
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
GUD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Knight Therapeutics reported strong financial performance with record revenues and EBITDA, significant growth driven by key products, and an improved financial outlook for 2025. The expansion of the oncology portfolio and increased credit facility provide a solid foundation for future growth. However, challenges were noted with regulatory setbacks in Brazil and Canada and a financial asset loss, though these do not overshadow the overall positive trends and achievements.View all TSE:GUD earnings summariesGUD Stock 12 Month Forecast
Average Price Target
C$8.49
▲(40.59% Upside)
Technical Analysis
Theratechnologies
―
Cipher Pharmaceuticals
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Options Prices
Currently, No data available
---